Akero Therapeutics Stock Buy Hold or Sell Recommendation
| AKRO Stock | USD 32.73 1.53 4.90% |
Given the investment horizon of 90 days and your highly speculative risk level, our recommendation regarding Akero Therapeutics is 'Hold'. The recommendation algorithm takes into account all of Akero Therapeutics' available fundamental, technical, and predictive indicators you will find on this site.
Check out Akero Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. To learn how to invest in Akero Stock, please use our How to Invest in Akero Therapeutics guide. In addition, we conduct extensive research on individual companies such as Akero and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Akero Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
Akero |
Execute Akero Therapeutics Buy or Sell Advice
The Akero recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Akero Therapeutics. Macroaxis does not own or have any residual interests in Akero Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Akero Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Hold
Market Performance | OK | Details | |
Volatility | Very steady | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Akero Therapeutics Trading Alerts and Improvement Suggestions
| Akero Therapeutics had very high historical volatility over the last 90 days | |
| Net Loss for the year was (151.76 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Akero Therapeutics currently holds about 180.72 M in cash with (145.37 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.81. | |
| Akero Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 95.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from investing.com: Akero Therapeutics chief development officer sells 251,274 in stock |
Akero Therapeutics Returns Distribution Density
The distribution of Akero Therapeutics' historical returns is an attempt to chart the uncertainty of Akero Therapeutics' future price movements. The chart of the probability distribution of Akero Therapeutics daily returns describes the distribution of returns around its average expected value. We use Akero Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Akero Therapeutics returns is essential to provide solid investment advice for Akero Therapeutics.
| Mean Return | 0.39 | Value At Risk | -4.45 | Potential Upside | 5.23 | Standard Deviation | 3.12 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Akero Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Akero Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument, such as Akero Therapeutics, soars without any apparent reason. This usually happens because many institutional investors are aggressively trading Akero Therapeutics back and forth among themselves. Companies that invest excess capital in these types of assets may also be included in this term and can influence corporate governance by exercising voting rights in their investments.
| Shares | Perceptive Advisors Llc | 2024-09-30 | 1.7 M | Boxer Capital Llc | 2024-09-30 | 1.7 M | Logos Global Management Lp | 2024-06-30 | 1.6 M | Geode Capital Management, Llc | 2024-09-30 | 1.6 M | Yiheng Capital Llc | 2024-06-30 | 1.4 M | Redmile Group, Llc | 2024-09-30 | 1.4 M | Point72 Asset Management, L.p. | 2024-09-30 | 1.3 M | T. Rowe Price Investment Management,inc. | 2024-09-30 | 1.3 M | Baker Bros Advisors Lp | 2024-09-30 | 1.1 M | Hhg Plc | 2024-06-30 | 6.9 M | Blackrock Inc | 2024-06-30 | 5.6 M |
Akero Therapeutics Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | (11.2M) | 122.5M | (36.8M) | 99.3M | (15.7M) | (14.9M) | |
| Free Cash Flow | (35.6M) | (71.0M) | (79.7M) | (92.5M) | (145.4M) | (138.1M) | |
| Other Non Cash Items | (104K) | 196K | 203K | 689K | (8.5M) | (8.0M) | |
| Net Income | (43.8M) | (79.2M) | (100.8M) | (112.0M) | (151.8M) | (144.2M) | |
| End Period Cash Flow | 64.8M | 187.4M | 150.6M | 249.9M | 234.2M | 151.4M | |
| Change To Netincome | 1.7M | 6.3M | 10.1M | 23.5M | 21.2M | 25.8M |
Akero Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Akero Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Akero Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Akero stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.13 | |
β | Beta against Dow Jones | 2.07 | |
σ | Overall volatility | 3.07 | |
Ir | Information ratio | 0.08 |
Akero Therapeutics Volatility Alert
Akero Therapeutics shows above-average downside volatility for the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Akero Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Akero Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Akero Therapeutics Fundamentals Vs Peers
Comparing Akero Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Akero Therapeutics' direct or indirect competition across all of the common fundamentals between Akero Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Akero Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Akero Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Akero Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Akero Therapeutics to competition |
| Fundamentals | Akero Therapeutics | Peer Average |
| Return On Equity | -0.36 | -0.31 |
| Return On Asset | -0.23 | -0.14 |
| Current Valuation | 1.6 B | 16.62 B |
| Shares Outstanding | 69.8 M | 571.82 M |
| Shares Owned By Insiders | 5.34 % | 10.09 % |
| Shares Owned By Institutions | 94.66 % | 39.21 % |
| Number Of Shares Shorted | 3.82 M | 4.71 M |
| Price To Earning | (7.43) X | 28.72 X |
| Price To Book | 3.09 X | 9.51 X |
| EBITDA | (148.63 M) | 3.9 B |
| Net Income | (151.76 M) | 570.98 M |
| Cash And Equivalents | 180.72 M | 2.7 B |
| Cash Per Share | 4.81 X | 5.01 X |
| Total Debt | 26.3 M | 5.32 B |
| Debt To Equity | 0.07 % | 48.70 % |
| Current Ratio | 6.90 X | 2.16 X |
| Book Value Per Share | 10.61 X | 1.93 K |
| Cash Flow From Operations | (145.37 M) | 971.22 M |
| Short Ratio | 8.02 X | 4.00 X |
| Earnings Per Share | (3.78) X | 3.12 X |
| Price To Earnings To Growth | 0.93 X | 4.89 X |
| Target Price | 48.27 | |
| Number Of Employees | 60 | 18.84 K |
| Beta | -0.26 | -0.15 |
| Market Capitalization | 2.28 B | 19.03 B |
| Total Asset | 580.27 M | 29.47 B |
| Retained Earnings | (574.1 M) | 9.33 B |
| Working Capital | 540.83 M | 1.48 B |
| Current Asset | 22.85 M | 9.34 B |
| Current Liabilities | 859.05 K | 7.9 B |
| Net Asset | 580.27 M |
Note: Disposition of 8890 shares by Catriona Yale of Akero Therapeutics at 0.615 subject to Rule 16b-3 [view details]
Akero Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Akero . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Akero Therapeutics Buy or Sell Advice
When is the right time to buy or sell Akero Therapeutics? Buying financial instruments such as Akero Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Akero Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Tech Growth Thematic Idea Now
Tech Growth
Instruments that are typically traded at high earnings multiples compared to their competitors and other sectors and have been known to drive market cycles frequently. The Tech Growth theme has 66 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Tech Growth Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Akero Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. To learn how to invest in Akero Stock, please use our How to Invest in Akero Therapeutics guide.You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Akero Therapeutics. If investors know Akero will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Akero Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.78) | Return On Assets (0.23) | Return On Equity (0.36) |
The market value of Akero Therapeutics is measured differently than its book value, which is the value of Akero that is recorded on the company's balance sheet. Investors also form their own opinion of Akero Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Akero Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Akero Therapeutics' market value can be influenced by many factors that don't directly affect Akero Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Akero Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Akero Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Akero Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.